Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on July 29, 2020, reporting events that occurred on July 27, 2020. The filing pertains to executive compensation and personnel changes within the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements rather than financial performance metrics.
Material Changes
On July 27, 2020, the Compensation Committee approved the following changes regarding Kevin Moran:
- Promotion: Mr. Moran was promoted from Vice President, Acting Chief Financial Officer and Treasurer to Senior Vice President, Chief Financial Officer and Treasurer.
- Salary Adjustment: His annual base salary was set at $390,000.
- Bonus Structure: He is eligible for an annual target bonus equal to 40% of his annual base salary.
- Equity Grants:
- Stock Option: 90,000 shares at an exercise price of $10.83 per share (closing price on July 27, 2020).
- Restricted Stock Units (RSUs): 17,344 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is limited to the disclosure of the amended employment agreement and equity awards.
Investor Verification Checklist
- Verify the vesting schedule for the 90,000 stock options (25% on July 27, 2021, then monthly over 36 months).
- Confirm the vesting schedule for the 17,344 RSUs (four equal annual installments starting July 27, 2021).
- Review the full text of the Amended and Restated Employment Agreement filed as Exhibit 10.1 for additional terms.
- Check the company's 2016 Equity Incentive Plan to understand the broader context of these grants.